Heinz Läubli is a physician scientist with clinical training and a specialisation in Medical Oncology and Internal Medicine. He is a Professor for Cellular Cancer Immunotherapies at the University Hospital Basel, heading the Laboratory for Cancer Immunotherapy and leading the GMP development/production for cell therapies at the Department of Biomedicine in Basel. A main focus of his research is to find approaches to remodel cancer-associated glycan changes to improve cancer immunotherapy.